December 2009 Issue of MMM
I got a golden ticket! Or rather, my senior editor Matthew Arnold did.
Healthcare marketing and communications execs, and pharma manufacturers, flocked to the sixth annual MM&M Awards gala presentation at New York City's Tavern on the Green ...
The healthcare reform legislation inching toward the president's desk will mean big changes for the pharmaceutical industry, whatever its final form. Matthew Arnold takes a ...
MM&M's Pipeline 2010 draws from the best in drug development, profiling 15 agents with the highest approval probability and brightest commercial prospects. These are the ...
In nearly 30 years working with medical devices, Tom Treusdell hasn't seen anything impact marketing more than electronic media.
I thought I would take a short step away from the usual drug analysis to discuss mammograms.
As the number of FDA-approved fibromyalgia therapies has grown, so has patient hope for relief from the ailment. However, the condition is still not well ...
Instead of merely slashing reps to trim costs, GlaxoSmithKline is relocating the positions, said CEO Andrew Witty.
Human Genome Sciences and GlaxoSmithKline are planning the launch of lupus drug Benlysta, and step one involves building a sales force to call on rheumatologists.
Featuring news about Shire, Eli Lilly and Warner Chilcott
Med Ed Report
A third attempt by an AMA ethics council asking physicians and medical institutions to curb industry funding for professional educational activities was rebuffed last month.
Dr. Charles Nemeroff, the psychiatrist whose undisclosed financial ties made him a national model for rethinking conflict-of-interest standards, this month joins the University of Miami ...
A new code ties disparate federal and state regulation, policy and other criteria into one document relevant to developing commercially supported CME.
Featuring news about the ACCME, North American Association of Medical Education and Communication Companies (NAAMECC), WebMD, and the health reform bill
To reach docs that may not have a laptop at the ready when medical information is needed, Elsevier optimized its MD Consult service for BlackBerrys, ...
Sage launched Therapeutic Advances in Musculoskeletal Disease, the seventh title in its Therapeutic Advances series.
Featuring news about Reed Elsevier, Wiley-Blackwell, Maney Publishing and Wolters Kluwer Health
Will healthcare reform—should it pass—serve as a tipping point in the shift from traditional brand messaging to customer-centric engagement?
Drugs.com, a free online drug-information database, will join the WebMD Health Network starting January 1, said WebMD.
HealthCentral.com partnered with 5min, a video production and syndication platform provider, to extend the reach of both companies in an increasingly cluttered online health environment.
Two Demand Media properties—Livestrong.com and eHow Health—are quickly moving up the list of most visited health sites online, according to comScore data.
Featuring news about AstraZeneca, Everyday Health, WebVet.com and Diabetes Mine
Over the years, we've seen a lot of disturbing images in DTC.
Prescription drug advertisers are running longer broadcast spots to accommodate more expansive fair balance statements, a Nielsen IAG analysis suggests, as 75-second spots proliferate.
The American Urological Association is partnering with the NFL for a GlaxoSmithKline-supported prostate cancer awareness campaign with the message that men should start getting tested ...
VNRs for King's ostensibly abuse-resistant pain drug Embeda drew an FDA warning letter.
Mulling celebrity spokes-candidates for an ad campaign? Consider this: business leaders are more persuasive than athletes, movie stars or musicians, according to a Harris Interactive ...
Featuring news about AdvaMed, Porter Novelli, Sanofi-Aventis, DDMAC, the American Medical Association and the Flu Information Care System
Pharmas, and their sales reps, need to understand the health economics of a product in differing contexts, according to panelists at the Pharmaceutical Marketing Research ...
IMS Health will be acquired by TPG Capital and the Canadian Pension Plan Investment Board, an investment management organization, for $5.2 billion.
One theory of career relativity states that the acquisition of an agency equals a management restructuring, and a management restructuring equals heads rolling.
Two interactive and social media agencies, Extrovertic and Virilion, have combined forces to create EV Healthcare, a consumer engagement shop.
As healthcare reform moves through Congress, power moves from the hands of committee chairmen to the speaker and the Senate majority leader, who will decide, ...
The ranking member of the Senate Finance Committee, Sen. Charles Grassley (R-IA) has asked state-level chapters of the National Alliance on Mental Illness (NAMI) to ...
FDA commissioner Margaret Hamburg says it is important for the nation to strengthen its commitment to regulatory science so that it becomes a robust and ...
Critics of the industry believe that our relationships with healthcare professionals taint their objectivity and result in overuse of branded drugs.
In my experience as director of communications for a national voluntary health organization, corporate/nonprofit partnerships were essential for helping the organization pursue its mission and ...
I'm old enough to remember a time when everybody in pharma suddenly had to have a website for their brand—not for any strategic reason, but ...
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy